Antisense Pharma raises €16.5m finance
German company Antisense Pharma has successfully raised €10m in the second closing of its current expansion financing, bringing the total to €16.5m.
German company Antisense Pharma has successfully raised €10m in the second closing of its current expansion financing, bringing the total to €16.5m.
The company intends to use the proceeds to continue the internal r&d programmes and clinical development of drug candidates focusing on malignant tumours.
'The excellent progress in our drug development impressed the existing and new investors and led to one of the biggest European financing rounds in the biopharmaceutical sector in 2003/2004,' said Dr Reimar Schlingensiepen, chief operating officer.
Data from preclinical and clinical studies of Antisense Pharma's most advanced antitumour agents, AP 12009 and AP 11014, were presented at the annual meeting of the American Association for Cancer Research in March.